Matches in SemOpenAlex for { <https://semopenalex.org/work/W2939203716> ?p ?o ?g. }
- W2939203716 endingPage "441" @default.
- W2939203716 startingPage "429" @default.
- W2939203716 abstract "Background In patients with type 2 diabetes, intensive glucose control can be renoprotective and albuminuria-lowering treatments can slow the deterioration of kidney function. We assessed the albuminuria-lowering effect of the sodium-glucose co-transporter-2 inhibitor dapagliflozin with and without the dipeptidyl peptidase-4 inhibitor saxagliptin, and the effect of dapagliflozin–saxagliptin on glycaemic control in patients with type 2 diabetes and moderate-to-severe chronic kidney disease. Methods In this double-blind, placebo-controlled trial (DELIGHT), we enrolled patients at 116 research centres in Australia, Canada, Japan, South Korea, Mexico, South Africa, Spain, Taiwan, and the USA. We included patients with a known history of type 2 diabetes, increased albuminuria (urine albumin-to-creatinine ratio [UACR] 30–3500 mg/g), an estimated glomerular filtration rate of 25–75 mL/min per 1·73 m2, and an HbA1c of 7·0–11·0% (53–97 mmol/mol), who had been receiving stable doses of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy and glucose-lowering treatment for at least 12 weeks. After a 4-week, single-blind placebo run-in period, participants were randomly assigned (1:1:1; via an interactive voice–web response system) to receive dapagliflozin (10 mg) only, dapagliflozin (10 mg) and saxagliptin (2·5 mg), or placebo once-daily for 24 weeks. Primary endpoints were change from baseline in UACR (dapagliflozin and dapagliflozin–saxagliptin groups) and HbA1c (dapagliflozin–saxagliptin group) at week 24 in all randomly allocated patients with available data (full analysis set). This study is registered with ClinicalTrials.gov, number NCT02547935 and is completed. Findings The study took place between July 14, 2015, and May 18, 2018. 1187 patients were screened, of whom 461 were randomly assigned: 145 to the dapagliflozin group, 155 to the dapagliflozin–saxagliptin group, and 148 to the placebo group (13 patients were excluded because of data integrity issues). Dapagliflozin and dapagliflozin–saxagliptin reduced UACR versus placebo throughout the study period. At week 24, the difference (vs placebo; n=134 patients with available data) in mean UACR change from baseline was −21·0% (95% CI −34·1 to −5·2; p=0·011) for dapagliflozin (n=132) and −38·0% (−48·2 to −25·8; p<0·0001) for dapagliflozin–saxagliptin (n=139). HbA1c was reduced in the dapagliflozin–saxagliptin group (n=137) compared with the placebo group (n=118) at week 24 (−0·58% [−0·80 to −0·37; p<0·0001]). The numbers of patients with adverse events (79 [54%] in the dapagliflozin group, 104 [68%] in the dapagliflozin–saxagliptin group, and 81 [55%] in the placebo group) or serious adverse events (12 [8%], 12 [8%], and 16 [11%], respectively) were similar across groups. There were no new drug-related safety signals. Interpretation Dapagliflozin with or without saxagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment, is a potentially attractive option to slow the progression of kidney disease in patients with type 2 diabetes and moderate-to-severe chronic kidney disease. Funding AstraZeneca. In patients with type 2 diabetes, intensive glucose control can be renoprotective and albuminuria-lowering treatments can slow the deterioration of kidney function. We assessed the albuminuria-lowering effect of the sodium-glucose co-transporter-2 inhibitor dapagliflozin with and without the dipeptidyl peptidase-4 inhibitor saxagliptin, and the effect of dapagliflozin–saxagliptin on glycaemic control in patients with type 2 diabetes and moderate-to-severe chronic kidney disease. In this double-blind, placebo-controlled trial (DELIGHT), we enrolled patients at 116 research centres in Australia, Canada, Japan, South Korea, Mexico, South Africa, Spain, Taiwan, and the USA. We included patients with a known history of type 2 diabetes, increased albuminuria (urine albumin-to-creatinine ratio [UACR] 30–3500 mg/g), an estimated glomerular filtration rate of 25–75 mL/min per 1·73 m2, and an HbA1c of 7·0–11·0% (53–97 mmol/mol), who had been receiving stable doses of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy and glucose-lowering treatment for at least 12 weeks. After a 4-week, single-blind placebo run-in period, participants were randomly assigned (1:1:1; via an interactive voice–web response system) to receive dapagliflozin (10 mg) only, dapagliflozin (10 mg) and saxagliptin (2·5 mg), or placebo once-daily for 24 weeks. Primary endpoints were change from baseline in UACR (dapagliflozin and dapagliflozin–saxagliptin groups) and HbA1c (dapagliflozin–saxagliptin group) at week 24 in all randomly allocated patients with available data (full analysis set). This study is registered with ClinicalTrials.gov, number NCT02547935 and is completed. The study took place between July 14, 2015, and May 18, 2018. 1187 patients were screened, of whom 461 were randomly assigned: 145 to the dapagliflozin group, 155 to the dapagliflozin–saxagliptin group, and 148 to the placebo group (13 patients were excluded because of data integrity issues). Dapagliflozin and dapagliflozin–saxagliptin reduced UACR versus placebo throughout the study period. At week 24, the difference (vs placebo; n=134 patients with available data) in mean UACR change from baseline was −21·0% (95% CI −34·1 to −5·2; p=0·011) for dapagliflozin (n=132) and −38·0% (−48·2 to −25·8; p<0·0001) for dapagliflozin–saxagliptin (n=139). HbA1c was reduced in the dapagliflozin–saxagliptin group (n=137) compared with the placebo group (n=118) at week 24 (−0·58% [−0·80 to −0·37; p<0·0001]). The numbers of patients with adverse events (79 [54%] in the dapagliflozin group, 104 [68%] in the dapagliflozin–saxagliptin group, and 81 [55%] in the placebo group) or serious adverse events (12 [8%], 12 [8%], and 16 [11%], respectively) were similar across groups. There were no new drug-related safety signals. Dapagliflozin with or without saxagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment, is a potentially attractive option to slow the progression of kidney disease in patients with type 2 diabetes and moderate-to-severe chronic kidney disease." @default.
- W2939203716 created "2019-04-25" @default.
- W2939203716 creator A5012551917 @default.
- W2939203716 creator A5016584401 @default.
- W2939203716 creator A5031624913 @default.
- W2939203716 creator A5039307237 @default.
- W2939203716 creator A5041913215 @default.
- W2939203716 creator A5069865054 @default.
- W2939203716 creator A5084032669 @default.
- W2939203716 creator A5085592050 @default.
- W2939203716 date "2019-06-01" @default.
- W2939203716 modified "2023-10-16" @default.
- W2939203716 title "Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial" @default.
- W2939203716 cites W1921395120 @default.
- W2939203716 cites W1945685354 @default.
- W2939203716 cites W2008687581 @default.
- W2939203716 cites W2017268330 @default.
- W2939203716 cites W2030192134 @default.
- W2939203716 cites W2081807710 @default.
- W2939203716 cites W2085015828 @default.
- W2939203716 cites W2090824142 @default.
- W2939203716 cites W2111663222 @default.
- W2939203716 cites W2146105386 @default.
- W2939203716 cites W2152096085 @default.
- W2939203716 cites W2152189242 @default.
- W2939203716 cites W2161852973 @default.
- W2939203716 cites W2418756187 @default.
- W2939203716 cites W2436309489 @default.
- W2939203716 cites W2492672367 @default.
- W2939203716 cites W2512006388 @default.
- W2939203716 cites W2523634442 @default.
- W2939203716 cites W2534221266 @default.
- W2939203716 cites W2595201361 @default.
- W2939203716 cites W2597545061 @default.
- W2939203716 cites W2626446274 @default.
- W2939203716 cites W2639738157 @default.
- W2939203716 cites W2733849831 @default.
- W2939203716 cites W2750733474 @default.
- W2939203716 cites W2756910166 @default.
- W2939203716 cites W2785119187 @default.
- W2939203716 cites W2794310633 @default.
- W2939203716 cites W2803265237 @default.
- W2939203716 cites W2807732548 @default.
- W2939203716 cites W2808915250 @default.
- W2939203716 cites W2900149048 @default.
- W2939203716 cites W2900413769 @default.
- W2939203716 cites W2908535040 @default.
- W2939203716 doi "https://doi.org/10.1016/s2213-8587(19)30086-5" @default.
- W2939203716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30992195" @default.
- W2939203716 hasPublicationYear "2019" @default.
- W2939203716 type Work @default.
- W2939203716 sameAs 2939203716 @default.
- W2939203716 citedByCount "127" @default.
- W2939203716 countsByYear W29392037162019 @default.
- W2939203716 countsByYear W29392037162020 @default.
- W2939203716 countsByYear W29392037162021 @default.
- W2939203716 countsByYear W29392037162022 @default.
- W2939203716 countsByYear W29392037162023 @default.
- W2939203716 crossrefType "journal-article" @default.
- W2939203716 hasAuthorship W2939203716A5012551917 @default.
- W2939203716 hasAuthorship W2939203716A5016584401 @default.
- W2939203716 hasAuthorship W2939203716A5031624913 @default.
- W2939203716 hasAuthorship W2939203716A5039307237 @default.
- W2939203716 hasAuthorship W2939203716A5041913215 @default.
- W2939203716 hasAuthorship W2939203716A5069865054 @default.
- W2939203716 hasAuthorship W2939203716A5084032669 @default.
- W2939203716 hasAuthorship W2939203716A5085592050 @default.
- W2939203716 hasBestOaLocation W29392037162 @default.
- W2939203716 hasConcept C126322002 @default.
- W2939203716 hasConcept C126894567 @default.
- W2939203716 hasConcept C134018914 @default.
- W2939203716 hasConcept C142724271 @default.
- W2939203716 hasConcept C159641895 @default.
- W2939203716 hasConcept C204787440 @default.
- W2939203716 hasConcept C27081682 @default.
- W2939203716 hasConcept C2776174234 @default.
- W2939203716 hasConcept C2777180221 @default.
- W2939203716 hasConcept C2777422806 @default.
- W2939203716 hasConcept C2778653478 @default.
- W2939203716 hasConcept C2779284873 @default.
- W2939203716 hasConcept C2780282729 @default.
- W2939203716 hasConcept C555293320 @default.
- W2939203716 hasConcept C71924100 @default.
- W2939203716 hasConceptScore W2939203716C126322002 @default.
- W2939203716 hasConceptScore W2939203716C126894567 @default.
- W2939203716 hasConceptScore W2939203716C134018914 @default.
- W2939203716 hasConceptScore W2939203716C142724271 @default.
- W2939203716 hasConceptScore W2939203716C159641895 @default.
- W2939203716 hasConceptScore W2939203716C204787440 @default.
- W2939203716 hasConceptScore W2939203716C27081682 @default.
- W2939203716 hasConceptScore W2939203716C2776174234 @default.
- W2939203716 hasConceptScore W2939203716C2777180221 @default.
- W2939203716 hasConceptScore W2939203716C2777422806 @default.
- W2939203716 hasConceptScore W2939203716C2778653478 @default.
- W2939203716 hasConceptScore W2939203716C2779284873 @default.
- W2939203716 hasConceptScore W2939203716C2780282729 @default.
- W2939203716 hasConceptScore W2939203716C555293320 @default.
- W2939203716 hasConceptScore W2939203716C71924100 @default.